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ABSTRACT
In a murine melanoma model, malignant transformation promoted by a sustained 
stress condition was causally related to increased levels of reactive oxygen species 
resulting in DNA damage and massive epigenetic alterations. Since the chromatin 
modifier Sirtuin-1 (SIRT1) is a protein attracted to double-stranded DNA break (DSB) 
sites and can recruit other components of the epigenetic machinery, we aimed to 
define the role of SIRT1 in melanomagenesis through our melanoma model. The 
DNA damage marker, γH2AX was found increased in melanocytes after 24 hours of 
deadhesion, accompanied by increased SIRT1 expression and decreased levels of 
its target, H4K16ac. Moreover, SIRT1 started to be associated to DNMT3B during 
the stress condition, and this complex was maintained along malignant progression. 
Mxd1 was identified by ChIP-seq among the DNA sequences differentially associated 
with SIRT1 during deadhesion and was shown to be a common target of both, SIRT1 
and DNMT3B. In addition, Mxd1 was found downregulated from pre-malignant 
melanocytes to metastatic melanoma cells. Treatment with DNMT inhibitor 5AzaCdR 
reversed the Mxd1 expression. Sirt1 stable silencing increased Mxd1 mRNA expression 
and led to down-regulation of MYC targets, such as Cdkn1a, Bcl2 and Psen2, whose 
upregulation is associated with human melanoma aggressiveness and poor prognosis. 
We demonstrated a novel role of the stress responsive protein SIRT1 in malignant 
transformation of melanocytes associated with deadhesion. Mxd1 was identified as 
a new SIRT1 target gene. SIRT1 promoted Mxd1 silencing, which led to increased 
activity of MYC oncogene contributing to melanoma progression.
INTRODUCTION
Sirtuin-1 (SIRT1) is an NAD-dependent class III 
histone deacetylase belonging to the protein family of 
sirtuins. It has usually been related to gene silencing 
through its deacetylase action on histones and non-histone 
targets. SIRT1 is well known to be responsive to stress 
and participates in the establishment and development of 
several tumors, including prostate, lung, breast, ovarian, 
hepatocellular carcinomas, and melanoma [1, 2, 3, 4, 5, 6]. 
Nevertheless, the role of SIRT1 in malignant transformation 
is controversially discussed and seems to be dependent on 
cell type and microenvironment (as reviewed by [7, 8]). It 
can promote tumor suppression [9, 10], but can also trigger 
malignant progression [3, 5, 11 12].  
Carcinogenesis is associated with specific 
mechanisms of intracellular stress status, such as 
oxidative stress, and its consequences, including 
epigenetic modifications and DNA damage [13, 14, 15, 
16]. The induction of a DNA double strand break in an 
exogenous E-cadherin promoter CpG island resulted in the 
relocation of SIRT1 to the site of damage, along with other 
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components of the epigenetic machinery, such as DNA 
methyltransferase 1 (DNMT1), DNA methyltransferase 
3B (DNMT3B), and Enhancer of zeste homolog 2 (EZH2) 
[17]. In this regard, it was reported that SIRT1 can relocate 
from regions non-rich in CGs to areas with high levels 
of CGs to increase their methylation [18]. Oberdoerffer 
and coworkers showed SIRT1 relocation in embryonic 
mesenchymal cells treated with hydrogen peroxide [19]. 
Here, SIRT1 dissociates from repetitive sequences and 
oncogenes and associates to DNA break regions, resulting 
in transcriptional changes similar to those observed during 
aging. Thus, SIRT1 relocation in response to oxidative 
stress might have a crucial role in the establishment 
of aberrant epigenetic patterns associated with the 
development of pathologies, including cancer. 
Particularly for melanomas, it was shown that 
increased oxidative stress leads to several mutations, 
which are related to tumor initiation and progression 
(reviewed by [20, 21, 22]). Previously, we reported that 
the induction of stress in non-tumorigenic melanocyte 
lineage melan-a via several cycles of cell adhesion 
impediment resulted in epigenetic reprogramming and 
malignant transformation [23, 24, 25, 26]. Through this 
protocol, different cell lines were established, such as 
pre-malignant 4C melanocyte lineage, non-metastatic 
4C11- and metastatic 4C11+ melanoma cell lines. In this 
in vitro melanocyte malignant transformation model, we 
demonstrated that after anchorage blockade, there was 
an increased level of reactive oxygen species, especially 
superoxide anion, which contributes to increased 
expression of DNMT1, DNMT3B and global content of 
methylated cytosine [27, 25]. These results suggested 
an important role of epigenetic modifications caused by 
environmental changes for the initiation of malignant 
transformation [23, 24]. Our previous studies have also 
shown increased SIRT1 expression during the initial 
phases of melanoma progression [25]. 
One of the major signaling pathways involved 
in cancer progression is the MYC/MAX/MAD 
network, which is related to cell growth, proliferation, 
differentiation, and apoptosis (reviewed by [29, 30]). 
The components MYC (Avian myelocytomatosis 
viral oncogene homolog) and MAD (or MXD, MAX 
dimerization protein 1) have antagonistic action, leading 
to transcriptional activation or silencing of several genes, 
respectively, by competing and interacting with MAX 
protein binding domain [31]. Myc acts as an oncogene 
and is frequently overexpressed in many types of cancer 
[32, 33, 34, 35]. In addition, Myc has been described as 
a candidate target for melanoma treatment [36]. It was 
shown that SIRT1 binds to the C-terminal region of MYC, 
which leads to MYC-MAX association and its subsequent 
activation [37].
Considering the fact that sustained stress of 
melanocytes leads to their malignant transformation 
and taking into account the potential role of SIRT1 in 
melanoma progression, this work aimed to evaluate the 
role of SIRT1 in our melanoma transformation model. For 
the first time, we show an interaction between SIRT1 and 
MYC/MAX/MAD network in melanoma progression, 
highlighting the SIRT1 role in the regulation of important 
pathways related to cancer.
RESULTS
SIRT1 shows increased expression and associates 
with DNMT3B during cellular stress caused by 
melanocyte adhesion blockade
In a first step, we evaluated DNA damage and SIRT1 
expression in melan-a melanocyte lineage subjected 
to adhesion blockade for 24 hours - a condition which, 
when repeated, results in malignant transformation [27]. 
An increase in γH2AX protein expression (Figure 1A), a 
characteristic mark of DNA double-strand breaks, as well 
as in SIRT1 protein expression (Figure 1B), was observed 
during deadhesion. This expression pattern indicates that 
deadhesion could lead to DNA damage and activates 
stress response via SIRT1. Indeed, as shown in Figure 
1C, a decrease in the acetylation of lysine 16 of histone 
4 (H4K16ac), a target of SIRT1, was observed during 
anchorage blockade, suggesting the increased SIRT1 
expression could be associated with an increase in its 
deacetylase activity. Moreover, SIRT1 becomes associated 
with DNMT3B during deadhesion (Figure 1D).
The cellular stress caused by melanocyte 
adhesion blockade leads to relocation of SIRT1 
to DNA sequences associated with cell survival, 
proliferation, and migration
The SIRT1 relocation was analyzed by ChIP-seq 
to determine the DNA sequences where SIRT1 is bound 
during deadhesion compared to adhered melanocytes. The 
results showed that SIRT1 binds to a greater number of 
DNA sequences during the stressful condition compared to 
normal adhesion conditions (Supplementary Table 1). Our 
in silico analysis showed that in normal condition, SIRT1 
tends to increase its association with DNA sequences 
next to genes related to pathways such as immune system 
process, transmembrane response and extracellular matrix 
organization (Figure 2A and Supplementary Table 2). 
While in the stress situation, SIRT1 has presented higher 
concentration value for sequences next to genes related 
to pathways involved in the establishment of cancer 
phenotype, like those related to migration, proliferation, 
angiogenesis, stress response, adhesion, invasion, 
carbohydrate metabolism, tumor growth, inflammation, 
chemotaxis, cell death, and cell survival (Figure 2A–2B, 
Supplementary Table 3). Among those pathways, our in 
silico analysis identified five SIRT1-associated genes (App, 
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Ncam1, Plat, Slc9a1 and Vegfc) that were concomitantly 
involved in the cellular processes migration, survival and 
proliferation (Figure 2C), further emphasizing the role 
of SIRT1 in the acquisition of malignant characteristics 
during cellular stress. Interestingly, an intronic region of 
the Mxd1 gene (represented by the purple bar in the Figure 
3B), an important modulator of MYC function [38], is 
among the sequences to which SIRT1 was found to be 
associated during stress condition (Figure 3A).
SIRT1 regulates Mxd1 during melanoma 
progression 
Since SIRT1 participates on stress response 
[18, 19], has elevated expression, increased Mxd1 
association in melanocytes submitted to stress condition, 
and is usually involved in gene silencing, as expected 
for histone deacetylase, we suggest that SIRT1 could 
participate in Mxd1 repression along melanocyte 
malignant transformation. To test this hypothesis, we 
evaluated Mxd1 gene expression by RT-qPCR. As shown 
in Figure 4A, the Mxd1 expression decreased along 
melanoma progression, being significantly reduced in 
pre-malignant 4C melanocytes and both non-metastatic 
4C11- and metastatic 4C11+ tumor cell lines compared 
with parental melan-a melanocytes. By ChIP assay, 
using primers targeting the same Mxd1 sequence found 
to be enriched in ChIP-seq (Figure 3B, primer sequences 
highlighted in orange), we showed that SIRT1 was more 
associated with Mxd1 in melanoma cell lines (non-
metastatic 4C11- and metastatic 4C11+ cells) compared 
to non-tumorigenic ones (melan-a melanocytes and 
pre-malignant 4C melanocytes) (Figure 4B). To further 
evaluate the effect of SIRT1 on Mxd1 expression, the 
melanoma cells 4C11- and 4C11+ were stable silenced 
for SIRT1 (Figure 4C and 4D). Sirt1 silencing increased 
expression of Mxd1 in both cell lines compared to non-
silenced cells (Figure 4E and 4F), pointing to a Mxd1 
repression by SIRT1 in melanoma cells.
Demethylating agent treatment reverses Mxd1 
repression 
As shown above, SIRT1 formed a new complex 
with DNMT3B during melanocyte deadhesion. To 
evaluate if this SIRT1-DNMT3B complex is maintained 
along melanoma progression, we performed protein co-
immunoprecipitation. In fact, protein-protein interaction 
between SIRT1 and DNMT3B was observed both in 
4C pre-malignant melanocytes and in 4C11- and 4C11+ 
tumor cells (Figure 5A). Interestingly, DNMT3B was 
found to be associated with Mxd1 gene at the same site 
where SIRT1 interacts, since we have used the same 
oligonucleotides designed for the sequence of Mxd1 
peak where SIRT1 has associated during stress condition 
(Figure 3B, primer sequences highlighted in orange). 
Similar to SIRT1, DNMT3B was stronger associated with 
Mxd1 in the tumor cell lines (Figure 5B). Moreover, Mxd1 
repression was reversed after treating tumor cell lines with 
the demethylating agent 5-Aza-2’deoxycytidine (Figure 
5C–5E). Analyses by pyrosequencing of Mxd1 promoter 
showed no significant difference in DNA methylation 
status, at least in this evaluated DNA sequence (Data not 
shown).
Figure 1: SIRT1 shows increased expression and associates with DNMT3B during stress condition. The expression of 
γH2AX (A), SIRT1 (B) and H4K16ac (C) were evaluated by western blot in adhered (ma) and deadhered (D24h) melan-a melanocytes. 
The expression of β-ACTIN or ERK was used as endogenous control. The interaction between SIRT1 and DNMT3B (D) was determined 
by co-immunoprecipitation in adherent (ma) and deadhered (D24h) melanocytes. Total: Total protein extract used in IP assay; IP: 
immunoprecipitated protein fraction.
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Down regulation of Mxd1 favors MYC activation
It is known that MXD1 competes with MYC 
oncoprotein for binding to MAX (MYC associated factor X). 
Since Mxd1 is downregulated by SIRT1 in 4C11- and 4C11+ 
tumor cell lines (Figure 4E and 4F), we have postulated 
that MAX could become more available to MYC binding 
in these melanoma cells. If a larger amount of MYC binds 
to MAX, we would expect an increased activation of MYC 
target genes. Among MYC targets, there are genes involved 
in tumorigenic processes, such as Cdkn1 (Cyclin Dependent 
Kinase Inhibitor 1A), Bcl2 (B-cell lymphoma 2) and Psen2 
(Presenilin-2). In our melanoma model, the expression 
of these genes is increased in the tumor cell lines (Figure 
6A) and, as hypothesized, there was a significant reduction 
of Cdkn1a, Bcl2 and Psen2 expression in SIRT1-silenced 
4C11+ melanoma cell line (Figure 6B–6D, respectively) 
compared to non-silenced cell lines. Together, these results 
show that SIRT1 is triggering MYC target gene expression by 
inhibiting MXD1 function, which may contribute to cancer 
phenotype acquisition. In line with this finding, in silico 
analysis of gene interactions between Sirt1, Myc and Max 
revealed several genes linked to tumor incidence (Figure 6E). 
Decreased levels of Mxd1 and increased levels 
of Myc-target genes in human melanomas are 
related to poor prognosis
From the Oncomine microarray public database 
analysis for human tumors [39], corroborating the results 
Figure 2: Under cellular stress, SIRT1 relocates to DNA sequences containing genes related to migration, survival, and 
proliferation. (A) Semantic similarities of Gene Ontology (GO) terms for the genes related to normal adhesion condition of melanocytes. 
The scatterplot shows the representative GO clusters in two-dimensional spaces. Bubble color indicates the p-value and the size indicates 
the frequency of GO terms. More semantically similar GO terms are closer in the plot. The mainly pathways found in adhesion were 
extracellular matrix organization, transmembrane transport and immune system process. The main pathways found under stress condition 
(deadhesion) were regulation of cell migration, proliferation, angiogenesis, negative regulation of cell death, regulation of growth, among 
others. (B) Biological pathways related to genes in which SIRT1 is associated during deadhesion. (C) Venn diagram showing the number 
of genes related to migration, survival and proliferation in which SIRT1 has associated to during deadhesion.
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Figure 3: Increased SIRT1 association to Mxd1 during stress condition. (A) Heatmap showing the intensity in which SIRT1 
was found to bind to Mxd1 DNA sequence in adhered (AD) and deadhered (D24h) melan-a melanocytes. (B) Mouse gene Mxd1 sequence. 
The purple rectangle represents the intronic region of the Mxd1 sequence where SIRT1 was differentially associated to before and during 
stress condition.  The oligonucleotide sequence of the peak is represented below, where the orange rectangle represents the regions over 
which the primers forward and reverse were designed to confirm SIRT1 and DNMT3B association to Mxd1 sequence, by Real time-qPCR. 
The green rectangle represents a CpG island where Mxd1 transcription start site lies on. The blue schedule represents complete Mxd1 gene, 
located in the chromosome 6. Figure modified from UCSC Genome browser (https://genome.ucsc.edu/).
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described above, Mxd1 seems to be reduced in melanoma 
cells and in metastatic cells, while Myc target genes 
are increased in cutaneous melanoma and seem to be 
associated with a poor prognosis (Figure 7).
DISCUSSION
Besides many advantages of existing mouse 
melanoma models, there are specific shortcomings 
regarding their recapitulation of natural tumor progression, 
from increasing proliferation to invasion and metastasis 
[44]. Our in vitro melanocyte malignant transformation 
model based on repeated cycles of anchorage blockade 
allows studying different stages of melanoma progression 
from normal melanocytes to non-metastatic and metastatic 
melanoma cells [27]. We do not use any carcinogenic 
agent or genetic engineering as stimulus, as the natural 
ability to survive anchorage blockade is a characteristic 
for disseminating tumor cells and finally leads to tumor 
transformation [45].
Previously, we have identified massive epigenetic 
alterations along tumor progression in our model [25]. 
Figure 4: SIRT1 regulates Mxd1 during melanoma progression. (A) Mxd1 expression in cell lines representing different phases 
of melanoma progression determined by RT-qPCR. (B) Association of SIRT1 to Mxd1 gene along malignant transformation was evaluated 
by ChIP. SIRT1 protein expression in non-metastatic 4C11- (C) and metastatic 4C11+ (D) cell lines after stable SIRT1 silencing using 
shRNA analyzed by western blot. Mxd1 expression in 4C11- (E) and 4C11+ (F) melanoma cell lines silenced for SIRT1 evaluated by 
RT-qPCR. ma: melan-a melanocyte lineage; 4C: pre-malignant melanocyte lineage; 4C11-: non-metastatic melanoma cell line; 4C11+: 
metastatic melanoma cell line; WT: wild type; Non-target: non-target shRNA control; sh#: SIRT1 silenced clones. *p < 0.01, **p < 0.001, 
****p < 0.00001.
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Particularly, DNA methyltransferases were deregulated 
after anchorage blockade as a result of increased levels 
of superoxide anion [27, 28]. Particularly, we observed 
a SIRT1 up-regulation in our melanoma progression 
model [25]. Similarly, Ohanna and coworkers reported 
SIRT1 overexpression in resistant BRAFV600E-mutated 
melanoma cells [6]. The role of the deacetylase SIRT1 
in cancer is not clearly understood and seems to be 
dependent on cell type and stimulus. To unravel the role 
of SIRT1 over-expression after anchorage blockade, we 
aimed to identify novel SIRT1 targets in different stages of 
melanoma development. For the first time, we unraveled 
that SIRT1 recruits DNMT3B and relocates to Mxd1 
gene under stress. MXD1 is a MYC inhibitor, competing 
with MYC for the binding of MAX co-activator. MYC/
MAX/MXD1 network has been shown to play a major 
role in the development of neuroblastoma and melanoma 
[36, 46]. A high c-MYC and SIRT1 protein co-expression 
has been demonstrated to be associated with malignant 
transformation of specific colorectal cancer subtypes [47]. 
Inversely, Li and coworkers reported a positive regulation 
of SIRT1 by the c-MYC pathway in acute myeloid 
leukemia [48]. Since in our model SIRT1 represses Mxd1 
gene expression, we suggest that MYC is activated in 
melanoma progression. As MYC is closely associated with 
tumor aggressiveness such as self-renewal capacity [49], 
proliferation [6] and epithelial to mesenchymal transition 
[50], we hypothesize that this newly identified interaction 
might lead to early initiation and finally to tumor 
progression in our model. Furthermore, our data suggest 
a new mechanism explaining how SIRT1 inactivates 
gene expression through recruitment of DNMT, i.e. by 
recruitment of DNMT3B to the Mxd1 gene promoter. 
DNMT3B is a de novo DNA methyltransferase, that is 
responsible for establishing new methylation patterns 
and is involved in gene silencing [51, 52]. Our data 
indicate that SIRT1 and DNMT3B co-participate in Mxd1 
epigenetic silencing in melanoma.
Our ChIP-seq data showed a SIRT1/Mxd1 
interaction already after 24 hours of anchorage 
blockade. Surprisingly, the ChIP assay along melanoma 
progression stages did not confirm this interaction in pre-
malignant 4C melanocytes, but SIRT1/Mxd1 interaction 
was remarkably evident at later stages. This genomic 
interaction might reflect high methylation dynamics 
along melanoma transformation and progression. The 
concept of high plasticity in methylation/demethylation 
in cancer has been highlighted very recently by Bell and 
coworkers [53] and Vizoso & Esteller [54]. Cells that are 
exposed to stressful conditions, like ROS induction by 
anchorage blockade in our model, need to adapt to these 
environmental alterations, which is mainly achieved by 
epigenetic reprogramming [55]. Indeed, SIRT1/DNMT3B 
complex was verified after 24h of anchorage blockade and 
at late stages of melanoma progression, but not at the pre-
malignant 4C cells, a result that we aforementioned for 
SIRT1/Mxd1 interaction. Corresponding to this, treatment 
of cells with DNMT inhibitor led to a continuous increase 
in Mxd1 expression along melanoma progression, 
suggesting sequential acquisition of aberrant epigenetic 
Figure 5: Demethylating agent treatment reverses Mxd1 repression by SIRT1. (A) The interaction between SIRT1 and 
DNMT3B determined by protein co-immunoprecipitation assay. (B) Association of DNMT3B to Mxd1 gene along the malignant 
transformation was evaluated by ChIP. Mxd1 expression after treatment for 48h with 10 µM 5AzaCdR analyzed by RT-qPCR in 4C (C), 
4C11- (D) and 4C11+ (E) cell lines. ma: non-tumorigenic melan-a melanocytes, 4C: pre-malignant melanocytes, 4C11-: non-metastatic 
melanoma cell line, 4C11+: metastatic melanoma cell line. Total: total protein extract used in IP assay; IP: immunoprecipitated protein 
fraction. *p < 0.01.
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marks. Moreover, Menssen and collaborators [56] found 
a positive feedback loop between SIRT1 and MYC 
activation in colorectal cancer. They described that SIRT1 
increases transcription activity of c-MYC, whereas c-MYC 
induces SIRT1 deacetylase activity. As a limitation of our 
study, we have to take into account that ChIP-seq showed 
500 bp long DNA binding region for SIRT1 at Mxd1 gene, 
whereas the ChIP assay verified only a smaller 100 bp 
DNA sequence in this region and we cannot exclude sub-
sequential stronger or transient binding of SIRT1 along the 
different stages of tumor progression. Depending on the 
ROS-induced DNA damage, the SIRT1 relocation at Mxd1 
Figure 6: Down-regulation of SIRT1 leads to an increase of Mxd1 expression and subsequent downregulation of MYC 
target genes. (A) Heatmap showing increased expression of MYC targets in 4C11+ melanoma cells compared to melan-a melanocytes 
obtained by microarray assays (color key chart with respective values is given). Arrows indicate Cdkn1a, Bcl2 and Psen2 as some of MYC 
targets in 4C11+ melanoma cells. Expression of Cdkn1a (B), Bcl2 (C) and Psen2 (D) was determined by RT-qPCR in non-metastatic 4C11- 
and metastatic 4C11+ melanoma cell lines, control and silenced for SIRT1. (E) Illustration of the interrelation among MYC and SIRT1 
target genes altered in our melanoma model by Ingenuity functional pathway analysis (IPA®) graphical database of networks of interacting 
genes (Ingenuity Knowledge Base, IKB®). Only genes with interactions are displayed and were further subjected to the built-in “Grow to 
Diseases & Functions” feature to detect genes related with “tumor incidence”. WT: wild type; non-target: non-target shRNA control; sh#: 
SIRT1 silenced clones. ***p < 0.0001, ****p < 0.00001.
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sequence and stress-induced SIRT1 recruited repressive 
protein complexes might vary along the different steps of 
melanoma progression. Altogether, we give experimental 
evidences that in our melanocyte malignant transformation 
model, based on sustained anchorage blockade SIRT1, 
is a major player for the acquisition of an aggressive 
phenotype. We propose a new mechanism of MYC 
oncogene activation by SIRT1-dependent epigenetic 
silencing of Mxd1 gene. 
Considering the reversibility of epigenetic 
changes, the participation of SIRT1 and other epigenetic 
components in reducing Mxd1 expression and in 
increasing MYC oncogenic activity might have prognostic 
and therapeutic potential in melanoma. 
MATERIALS AND METHODS
In vitro melanoma progression model 
The studies were performed using an in vitro 
malignant melanoma progression model, previously 
established by our research group [27]. In this model, the 
melanocyte malignant transformation occurs without using 
physical or chemical carcinogenic agents and without 
Figure 7: Decreased levels of Mxd1 and increased levels of Myc-target genes in human melanomas are related to poor 
prognosis. Data obtained from Oncomine database [40, 41, 42, 43] are shown across multiple independently published microarray studies 
as indicated. Boxes represent the interquartile range (25th–75th percentile). The bars denote the median. P <-1E4
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genetic manipulation. The non-tumorigenic melanocyte 
lineage melan-a, derived spontaneously from epidermal 
melanoblasts of mouse embryos [57], was submitted 
to a sustained stress situation, represented by cycles of 
successive adhesion blockade. The melan-a cells, that in 
normal condition grow adherent to the plate ground, were 
maintained in suspension for 96 hours. As expected for 
immortalized non-tumorigenic cell line, the vast majority 
of cells died by anoikis after 96 hours in suspension. After 
this time, the few surviving cells were plated again in 
adherent condition. Those cells were called 1C (subjected 
to one cycle of anchorage blockade). When the plate 
achieved 80% of cell confluence, the cells were trypsinized 
and replated in deadhesion condition for 96 hours and the 
surviving cells were plated again in adherent condition and 
called 2C. These steps were repeated a third and fourth 
time, giving rise to 3C and 4C cell lines, submitted to three 
and four cycles of deadhesion, respectively. Subsequently, 
4C cells were subjected to a fifth cycle of anchorage 
blockade for 96 hours and the surviving spheroids were 
submitted to a limiting dilution. After this, all randomly 
selected clones (among them 4C11-) were shown to be 
tumorigenic when injected into syngeneic mice and some 
of them were able to form metastatic colonies in the lung 
when injected in the caudal vein (as 4C11+). Besides 
forming tumoral colonies in the lung after intravenous 
inoculation, metastatic foci in axillary lymph nodes, 
confirmed by histological analysis, were found after 
subcutaneous inoculation of 4C11+ cells, demonstrating 
its metastatic phenotype. All the lineages derived from 
melan-a have shown stable phenotype, since they have 
maintained their morphology, expression of a panel of 
genes and proteins, and the same behavior in functional 
assays (such as proliferation, migration, invasion, anoikis 
resisitance, etc) along time.
Cell culture 
The cell lines used in this study were the non-
tumorigenic melan-a melanocytes, the pre-malignant 4C 
melanocytes, the non-metastatic 4C11- melanoma cell line, 
and the metastatic 4C11+ melanoma cell line. The cells 
were cultured in RPMI pH 6.9 (Gibco, Carlsbad, CA), 
with 5% fetal bovine serum (FBS) (Gibco) and, just for 
melan-a, 200 nM phorbol 12-myristate 13-acetate – PMA 
(Amresco) was added. The PMA was added to the medium 
only for melan-a because it is necessary for proliferation 
and survival of cultured non-tumoral melanoblasts 
and melanocytes. Melan-a cells do not form tumors in 
syngeneic or athymic mice even after a long time being 
cultured in the presence of PMA (Bennett, Cooper, and 
Hart 1987). On the other hand, as described for melanoma 
cells, the cell lines obtained after four 96-hours cycles 
of adhesion blockade were capable of proliferating and 
avoiding senescence in the absence of PMA. All cell 
lines were grown at 37oC, under humidified atmosphere 
with 5% of CO2 until utilized in the experiments. Unless 
mentioned, all cell lines were cultivated in adherent 
conditions.
Western blot 
Protein extracts, prepared with RIPA buffer (50 mM 
Tris HCl (pH 7,4); 50 mM NaCl; 1% NP40 10%; 0.5% 
sodium deoxycolate 10%; 0.1% SDS 1%) containing 
protease inhibitors (PMSF 1 mM, Na3VO4 1 mM, 
pepstatin 10 mg/ml, leupeptin 10 mg/ml, aprotinin 10 
mg/ml), were separated by electrophoresis in SDS-PAGE 
polyacrylamide gel and transferred to a PVDF membrane. 
Then, each membrane was blocked for 40 minutes in a 
solution with 5% of non-fat milk. Next, primary antibody 
was added to the membranes and incubated according 
to manufacturer’s instructions. The membranes were 
washed and the secondary antibody was incubated for 
one hour, according to manufacturer’s instructions. 
Primary antibodies used were: anti-phospho-H2AX 
(Ser139) (Merck Millipore, 07–164), anti-SIRT1 (Abcam, 
#Ab12193), anti-DNMT1 (Imgenex, IMG-261A), 
anti-DNMT3B (Active Motif, #39207), anti-H4K16ac 
(Millipore, Temecula, CA, #07–329). After secondary 
antibodies incubation (KPL), the membranes were washed 
with TBS-T, detected with chemiluminescent SuperSignal 
(ThermoScientific) and visualized by luminescence 
reading device UVITEC (Cambridge, www.uvitec.co.uk). 
Protein co-immunoprecipitation 
The association between SIRT1 and DNMT3B 
proteins was verified by protein co-immunoprecipitation 
assay. For this purpose,  Protein G – agarose beads 
(10007D, Life Technologies) were used and the assay was 
performed according to the manufacturer’s instructions. 
Immunoprecipitation was performed with anti-SIRT1 
(Abcam, #ab12–193), anti-DNMT1 (Imgenex, IMG-
261A) or anti-DNMT3B (Active Motif, #39207), 
following datasheet specifications. The samples were used 
for subsequent analyses following western blot procedure. 
Chromatin immunoprecipitation (ChIP) 
ChIP assay was performed with Active Motif kit 
(ChIP-IT® High Sensitivity, catalog no. 53040), according 
to the manufacturer’s instructions. The ChIP assay was 
performed in independent duplicates.
Chromatin immunoprecipitation followed by 
DNA sequencing (ChIP-seq) 
ChIP-seq assay was performed with Active Motif 
kit (ChIP-IT® High Sensitivity, catalog no. 53040), 
according to the manufacturer’s instructions. ChIP-seq 
assay was performed in independent duplicates. DNA 
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from ChIP was prepared from melan-a melanocytes 
and from melan-a melanocytes submitted to anchorage 
blockade during 24 hours, as described by ChIP-IT® High 
Sensitivity (Active Motif – 53040) protocol. After ChIP, 
enrichment for known targets was verified with INPUT 
(total DNA extract) and IgG samples by qPCR assay 
before sequencing. For pPCR reactions, we have used 
1/10 input dilution. The qPCR results were normalized 
with the percentage of input amplification (sample signal 
value from IP assay was divided by input sample signal 
value). The DNA samples immunoprecipitated with anti-
SIRT1 have been sequenced on a SOLiD4 machine from 
Life Technologies (Life Technologies, Carlsbad, CA, 
USA). Libraries for ChIP-seq were prepared following 
protocols recommended by SOLiD4. For alignment 
and mapping, the LifeScope mapper was used to map 
the reads across reference GRCm38/mm10 mouse 
genome. Then, Samtool package was used to sort and 
to remove the duplicates reads to improve specificity 
[58]. The reads quality was verified by FASTQC and 
the good mapping quality scores were considered Phred 
values ≥ 20 [59]. From BAM files alignment, Peak 
Caller MACs (Model basic analysis of ChIP-seq) was 
used to find regions in the genome with a significant 
number of mapped reads [60]. After normalizing and 
eliminating background, the redundant peaks were 
removed. Next, we used the open source software 
package Diffbind (Differential binding analysis of ChIP-
seq peak data) from Bioconductor to count, adjust the 
contrast and to analyze the DNA sequences where SIRT1 
was differentially bound [61]. DSEQ2, a Bioconductor 
package [62], was used to identify ChIP peaks associated 
with SIRT1. Finally, the packages Genomic Ranges and 
org.Mm were used to identify the gene closest to each of 
those peaks, considering GRCm38/mm10 mouse as the 
reference genome [63]. 
Gene Ontology (GO) analysis 
The GO analysis was performed to evaluate the 
mainly pathways that the closest genes to the peaks where 
SIRT1 has associated in normal and suspension condition 
were involved. For this, firstly we have used DAVID tool 
to obtain GO terms and p-values for each gene, according 
the procedure recommended [64, 65]. Then, we have used 
the obtained GO terms and p-values (less or equal to 0.05) 
for REVIGO analysis.  Based on algorithms that reduce 
redundance, REVIGO finds a subset of representative and 
non-redundant GO terms as described previously [66]. 
The results were represented by two scatterplots, one for 
adhesion and other for deadhesion condition, showing the 
representatives clusterings remaining after the redundance 
reduction. More semantically similar GO terms are closer 
in the plot. The bubble size indicates the frequency of the 
GO term, while the color represents the p-value according 
to legend.
In silico functional pathway analysis 
For in silico functional pathway analysis of 
pathways related to SIRT1-associated genes, as well 
as interaction analysis of SIRT1/MYC/MAX we used 
Ingenuity Pathway Analysis (IPA) software (Qiagen, 
Redwood City, CA, USA), as previously described [67]. 
5-AzaCdR and TSA treatment 
The compound 5-AZA-2’deoxycytidine (5-AzaCdR) 
is an inhibitor of DNA methylation, while Trichostatin A 
(TSA) inhibits HDACs of class I, II and IV. To evaluate 
the effect of methylation and histone modification on 
gene expression, the melan-a, 4C, 4C11- and 4C11+ cell 
lines were treated with 5-AzaCdR and TSA, respectively, 
or with 5-AzaCdR and TSA concomitantly to verify 
if the effect of the treatment with both drugs would be 
amplified. Treatment was started at 40% confluence. The 
compound 5-AzaCdR was added to the plate at 10 µM 
final concentration in 10 ml of RPMI medium enriched 
with 5% FBS and the cells were cultivated for 24 hours 
in a humidified incubator at 37oC with 5% CO2. Every 
24 hours, the medium was changed with the addition of 
5-AzaCdR at the same conditions. For the treatment with 
TSA, the compound was added to the plate at the final 
concentration of 40 nM and the cells were maintained at 
the same conditions described before. For the treatment 
with 5-AzaCdR and TSA, the cells were primarily treated 
with 5-AzaCdR and, after 96 hours the medium was 
removed and the TSA was added, as described before. 
Subsequently, total RNA was extracted from the cells 
following TRIzol® recommended protocol.
Quantitative Real Time PCR 
Quantitative analysis of mRNA expression was 
performed using the Corbett Rotor-Gene 6000 system 
detection using Rotor-Gene kit Fast Syber Green PCR 
Master Mix® (Qiagen, Dusseldorf, Germany). 
Pyrosequencing 
Pyrosequencing assay was performed with 
PyroMark Gold Q24 Qiagen kit (catalog number 
1055272), according to the manufacturer’s instructions.
Sirt1 stable silencing 
The stable silencing of Sirt1 was performed by 
MISSION® shRNA Lentiviral Transduction Particles 
from Sigma-Aldrich (SHCLNV-NM_019812). Lentiviral 
particles were used to establish cell lines with knockdown 
of Sirt1 or expressing the non-target shRNA sequence as 
a control. All transductions were performed using a MOI 
(multiplicity of infection) of 0.5, in the presence of 8 µg/
mL polybrene. After transduction, puromycin-resistant 
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cells were selected. The target silencing was checked by 
RT-qPCR.
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